Feng Shi

1.3k total citations
36 papers, 767 citations indexed

About

Feng Shi is a scholar working on Molecular Biology, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Feng Shi has authored 36 papers receiving a total of 767 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 14 papers in Oncology and 11 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Feng Shi's work include Thyroid Cancer Diagnosis and Treatment (11 papers), RNA modifications and cancer (9 papers) and Viral-associated cancers and disorders (7 papers). Feng Shi is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (11 papers), RNA modifications and cancer (9 papers) and Viral-associated cancers and disorders (7 papers). Feng Shi collaborates with scholars based in China, United States and Saudi Arabia. Feng Shi's co-authors include Ya Cao, Ann M. Bode, Xiangjian Luo, Yueshuo Li, Min Tang, Longlong Xie, Jianmin Hu, Lin Zhao, Xinfang Yu and Jia Fan and has published in prestigious journals such as Journal of Clinical Oncology, Environmental Science & Technology and Scientific Reports.

In The Last Decade

Feng Shi

35 papers receiving 759 citations

Peers

Feng Shi
Gonzalo Carrasco-Aviño Chile
Manabu Iwadate Japan
Diana M. Merino United States
Sumio Kawata Japan
Haijian Wang China
Jinzhi Wang China
Ryoko Saito Japan
Susmita Chakrabarti United States
Haihui Sheng China
Marc Rio France
Gonzalo Carrasco-Aviño Chile
Feng Shi
Citations per year, relative to Feng Shi Feng Shi (= 1×) peers Gonzalo Carrasco-Aviño

Countries citing papers authored by Feng Shi

Since Specialization
Citations

This map shows the geographic impact of Feng Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feng Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feng Shi more than expected).

Fields of papers citing papers by Feng Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feng Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feng Shi. The network helps show where Feng Shi may publish in the future.

Co-authorship network of co-authors of Feng Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Feng Shi. A scholar is included among the top collaborators of Feng Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feng Shi. Feng Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhou, Yichen, et al.. (2025). An update on the clinical trial research of immunotherapy for glioblastoma. Frontiers in Immunology. 16. 1582296–1582296. 6 indexed citations
2.
Xie, Lili, Yu Zou, Fu‐Rong Li, et al.. (2025). Analysis of the relationships between the degree of migraine with right-to-left shunts and changes in white matter lesions and brain structural volume. Scientific Reports. 15(1). 1145–1145. 1 indexed citations
3.
Fu, Chaowei, Dongbo Liu, Qi Liu, et al.. (2024). Revisiting an old relationship: the causal associations of the ApoB/ApoA1 ratio with cardiometabolic diseases and relative risk factors—a mendelian randomization analysis. Cardiovascular Diabetology. 23(1). 51–51. 4 indexed citations
4.
Hu, Xudong, Yueshuo Li, Ya Cao, Feng Shi, & Shang Li. (2024). The role of nitric oxide synthase/ nitric oxide in infection-related cancers: Beyond antimicrobial activity. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1879(5). 189156–189156. 9 indexed citations
5.
Shi, Feng, Delbert Almerick T. Boncan, Hin Ting Wan, et al.. (2022). Hepatic metabolism gene expression and gut microbes in offspring, subjected to in-utero PFOS exposure and postnatal diet challenges. Chemosphere. 308(Pt 1). 136196–136196. 8 indexed citations
6.
Li, Yueshuo, Feng Shi, Jianmin Hu, et al.. (2021). Stabilization of p18 by deubiquitylase CYLD is pivotal for cell cycle progression and viral replication. npj Precision Oncology. 5(1). 14–14. 14 indexed citations
7.
Zheng, Xiangqian, Zhengang Xu, Qinghai Ji, et al.. (2021). A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer. Clinical Cancer Research. 27(20). 5502–5509. 31 indexed citations
8.
Zhao, Lin, Xiangying Deng, Yueshuo Li, et al.. (2021). Conformational change of adenine nucleotide translocase‐1 mediates cisplatin resistance induced by EBV‐LMP1. EMBO Molecular Medicine. 13(12). e14072–e14072. 15 indexed citations
9.
Cao, Ya, Longlong Xie, Feng Shi, et al.. (2021). Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study. Signal Transduction and Targeted Therapy. 6(1). 15–15. 74 indexed citations
10.
Shi, Feng, Jiangjiang Li, Min Tang, et al.. (2020). Wild-type IDH2 contributes to Epstein–Barr virus-dependent metabolic alterations and tumorigenesis. Molecular Metabolism. 36. 100966–100966. 23 indexed citations
11.
12.
13.
14.
Chi, Yihebali, Ming Gao, Feng Shi, et al.. (2020). LBA88 Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial. Annals of Oncology. 31. S1215–S1215. 6 indexed citations
15.
Xie, Longlong, Feng Shi, Yueshuo Li, et al.. (2020). Drp1-dependent remodeling of mitochondrial morphology triggered by EBV-LMP1 increases cisplatin resistance. Signal Transduction and Targeted Therapy. 5(1). 56–56. 89 indexed citations
16.
Du, Qianqian, Zheqiong Tan, Feng Shi, et al.. (2019). PGC1α/CEBPB/CPT1A axis promotes radiation resistance of nasopharyngeal carcinoma through activating fatty acid oxidation. Cancer Science. 110(6). 2050–2062. 82 indexed citations
17.
Shi, Feng, Min Zhou, Shang Li, et al.. (2019). EBV(LMP1)-induced metabolic reprogramming inhibits necroptosis through the hypermethylation of the RIP3 promoter. Theranostics. 9(9). 2424–2438. 49 indexed citations
18.
Liu, Xiaolan, Yueshuo Li, Xinfang Yu, et al.. (2018). Epstein-Barr virus encoded latent membrane protein 1 suppresses necroptosis through targeting RIPK1/3 ubiquitination. Cell Death and Disease. 9(2). 53–53. 62 indexed citations
19.
Luo, Xiangjian, Can Cheng, Namei Li, et al.. (2018). DNMT1 mediates metabolic reprogramming induced by Epstein–Barr virus latent membrane protein 1 and reversed by grifolin in nasopharyngeal carcinoma. Cell Death and Disease. 9(6). 619–619. 75 indexed citations
20.
Zhu, Cuige, Xiaoyan Deng, & Feng Shi. (2008). Evaluation of the antioxidant activity of Chinese Hickory ( Carya cathayensis ) kernel ethanol extraction. AFRICAN JOURNAL OF BIOTECHNOLOGY. 7(13). 2169–2173. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gonzalo Carrasco-Aviño Breakdown of academic impact, for papers by Manabu Iwadate Breakdown of academic impact, for papers by Diana M. Merino Breakdown of academic impact, for papers by Sumio Kawata Breakdown of academic impact, for papers by Haijian Wang Breakdown of academic impact, for papers by Jinzhi Wang Breakdown of academic impact, for papers by Ryoko Saito Breakdown of academic impact, for papers by Susmita Chakrabarti Breakdown of academic impact, for papers by Haihui Sheng Breakdown of academic impact, for papers by Marc Rio
Rankless by CCL
2026